Blood–brain barrier transcytosis genes, risk of dementia and stroke: a prospective cohort study of 74,754 individuals
Year: 2019
Type: article
Study design: Observational Study
Abstract: To test whether genetic variants in PICALM, BIN1, CD2AP, and RIN3-suggested to be involved in blood-brain barrier amyloid-β transcytosis pathways-associate with Alzheimer's disease, all dementia, suggested vascular dementia, and stroke, and whether such associations are independent of the strong ε4 APOE risk allele. In a prospective cohort study of 74,754 individuals from the general population we genotyped PICALM (rs10792832), BIN1 (rs6733839), CD2AP (rs10948363), and RIN3 (rs10498633), and generated a weighted and a simple allele score. Multifactorially adjusted hazard ratios for the fourth quartile versus the first quartile of the weighted allele score were 1.42 (95% confidence interval 1.22-1.64) for Alzheimer's disease, and 1.33 (1.19-1.48) for all dementia. For suggested vascular dementia and stroke the corresponding estimates were 1.71 (1.18-2.49) and 1.12 (1.04-1.22), respectively. Hazard ratios were similar after APOE adjustment. Genetic variants in PICALM, BIN1, CD2AP, and RIN3 are associated with increased risk of Alzheimer's disease, all dementia, and suggested vascular dementia independent of the strong APOE ε4 allele. These findings may suggest that clathrin-mediated endocytosis in clearance of amyloid-β across the blood-brain barrier is important for the integrity of both brain tissue and cerebral vessels.
Source: European Journal of Epidemiology
Language: English
Subfield: Cellular and Molecular Neuroscience
Field: Neuroscience
Domain: Life Sciences
Open Access status: hybrid
Estimated APC paid: $4,390
Funders: Sundhed og Sygdom, Det Frie Forskningsråd, Wellcome Trust, Development of Innovative Strategies for a Transdisciplinary approach to ALZheimer's disease, Université de Lille, Institut National de la Santé et de la Recherche Médicale, Alzheimer’s Research UK, Bundesministerium für Bildung und Forschung, Erasmus Medisch Centrum, Lundbeckfonden, Rigshospitalet, Hjartavernd, H. Lundbeck A/S, Centre hospitalier régional universitaire de Lille, Fondation pour la Recherche sur Alzheimer, National Institutes of Health, Medical Research Council, National Institute on Aging, National Heart, Lung, and Blood Institute
Awards: G1108310052, Kompetenznetz 'Demenzen', THE AGES STUDY - THE REYKJAVIK STUDY OF HEALTHY AGING FOR THE NEW MILLENUM, G1901425420, G230712557, G250924255, G2697093250, G3161882281, G3238051710, National Alzheimer's Coordinating Center, G3386955339, G3402222819, G3624871761, G4838234079, Alzheimer's Disease Genetics Consortium, CHARGE consortium: omics discovery for CVD and aging phenotypes, G6145417777, A Powerful, Genome-Wide Association Scan for Susceptibility Genes for late-onset Alzheimer's disease, Verbundprojekt: Kompetenznetz Demenzen - Epidemiologie: Teilprojekte der Universität Bonn, Verbundprojekt Kompetenznetz Demenzen: Teilprojekte des ZISG Mannheim (2. Förderphase), G7373387228, AD Gene Discovery: Exome Chip, New Endophenotypes & Functional Studies in CHARGE, G863491659, G8951052545, National Centralized Repository for Alzheimer's Disease and Related Dementias (NCRAD)
OpenAlex ID: W2918948463
